Clinical and functional determinants of coronary flow reserve in non-ischemic dilated cardiomyopathy - An echocardiographic study

被引:26
|
作者
Santagata, P
Rigo, F
Gherardi, S
Pratali, L
Drozdz, J
Varga, A
Picano, E
机构
[1] CNR, Inst Clin Physiol, I-56124 Pisa, Italy
[2] Univ Szeged, Szeged, Hungary
[3] Univ Lodz, PL-90131 Lodz, Poland
关键词
coronary flow reserve; dilated carchomyopathy; dipyridamole; echocardiography;
D O I
10.1016/j.ijcard.2004.11.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Coronary flow reserve (CFR) is impaired in non-ischemic dilated cardiomyopathy (DCM). Mechanisms by which such impairment occurs are still unknown, but cofactors; such as diastolic compressive force, left ventricular hypertrophy, and microvascular disease have been implied. In order to characterize the determinants of CFR in non-ischemic DCM, we evaluated 110 non-ischemic DCM patients (58 men; age=61 +/- 12 years) and 21 age- and gender-matched control patients (14 men; age=59 +/- 13 years) by transthoracic (n=88) or transesophageal (n=22) dipyridamole (0.84 mg/kg in 10') stress echocardiography. All patients showed angiographically normal coronary arteries. Non-ischemic DCM patients had an ejection fraction < 45% while control patients had normal left ventricular systolic function. CFR was assessed on LAD by pulsed Doppler as the ratio of maximal vasodilation (dipyridamole) to rest peak diastolic coronary flow velocity. Mean CFR value was 2.0 +/- 0.6 for DCM patients and 3.2 +/- 0.5 for controls (p < 0.01). At individual non-ischemic DCM patient analysis, 46 patients had normal CFR >= 2 (Group 1) and 64 patients had abnormal CFR < 2 (Group 2). On univariate analysis, CFR reduction correlated with NYHA functional class (r=-0.33, p=0.001), left ventricular ejection fraction ( r=0.23, p=0.02), end-systolic volume (r=-0.23, p=0.02), systolic pulmonary artery pressure (r=-0.42, p=0.0001), deceleration time (r=0.24, p=0.02). Logistic multiregression analysis showed that only NYHA functional class significantly and negatively correlated with CFR (odds ratio=0.9; 95% confidence intervals: 0.03-.35, p=0.0001). In patients with non-ischemic DCM, CFR is reduced but with substantial individual variability, only partially accounted for by level of systolic and diastolic dysfunction. The clinical functional class is the strongest predictor of CFR reduction in these patients, with lowest flow reserve found in more advanced NYHA class. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:46 / 52
页数:7
相关论文
共 50 条
  • [21] Determinants of Atrial Electromechanical Delay in Patients with Functional Mitral Regurgitation and Non-ischemic Dilated Cardiomyopathy
    Bakal, Ruken Bengi
    Hatipoglu, Suzan
    Sahin, Muslum
    Emiroglu, Mehmet Yunus
    Bulut, Mustafa
    Ozdemir, Nihal
    JOURNAL OF CARDIOVASCULAR AND THORACIC RESEARCH, 2014, 6 (04) : 241 - 246
  • [22] Left Atrial Volume Determinants in Patients with Non-Ischemic Dilated Cardiomyopathy
    Neves Mancuso, Frederico Jose
    Moises, Valdir Ambrosio
    Almeida, Dirceu Rodrigues
    Poyares, Dalva
    Storti, Luciana Julio
    Oliveira, Wercules Antonio
    Brito, Flavio Souza
    Vincenzo de Paola, Angelo Amato
    Camargo Carvalho, Antonio Carlos
    Campos, Orlando
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2015, 105 (01) : 65 - 70
  • [23] Assessment of coronary blood flow in non-ischemic dilated cardiomyopathy with the TIMI frame count method
    Yasar, Ayse Saatci
    Bilen, Emine
    Yuksel, Isa Oner
    Ipek, Gokturk
    Kurt, Mustafa
    Ipek, Emrah
    Bilge, Mehmet
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2010, 10 (06): : 514 - 518
  • [24] Genetic stress echocardiography: role of A2a receptors polymorphism in modulating coronary flow reserve response in non-ischemic dilated cardiomyopathy
    Andreassi, M. G.
    Foffa, I.
    Gherardi, S.
    Manfredi, S.
    Rigo, F.
    Lazzerini, G.
    Pasanisi, E.
    Pasini, F. Laghi
    Picano, E.
    EUROPEAN HEART JOURNAL, 2007, 28 : 424 - 424
  • [25] GCSF treatment for non-ischemic dilated cardiomyopathy
    Tomita, S
    CARDIOVASCULAR DRUGS AND THERAPY, 2006, 20 (02) : 83 - 84
  • [26] GCSF Treatment for Non-Ischemic Dilated Cardiomyopathy
    Shinji Tomita
    Cardiovascular Drugs and Therapy, 2006, 20 : 83 - 84
  • [27] ICD Therapy for Non-Ischemic Dilated Cardiomyopathy
    Abboud, Jaber
    Boehmer, Andreas A.
    Georgopoulos, Stamatis
    Ehrlich, Joachim R.
    AKTUELLE KARDIOLOGIE, 2020, 9 (06) : 534 - 538
  • [28] Results of the DERIVATE study in non-ischemic dilated cardiomyopathy (NICM)
    Guaricci, A. I.
    Masci, P. G.
    Lorenzoni, V.
    Schwitter, J.
    Pontone, G.
    EUROPEAN HEART JOURNAL, 2019, 40 : 2566 - 2566
  • [29] Non-ischemic dilated cardiomyopathy and cardiac fibrosis
    Bianca Olivia Cojan-Minzat
    Alexandru Zlibut
    Lucia Agoston-Coldea
    Heart Failure Reviews, 2021, 26 : 1081 - 1101
  • [30] Left Ventricular Torsion - A New Echocardiographic Prognosticator in Patients With Non-Ischemic Dilated Cardiomyopathy -
    Rady, Mohamed
    Ulbrich, Stefan
    Heidrich, Felix
    Jellinghaus, Stefanie
    Ibrahim, Karim
    Linke, Axel
    Sveric, Krunoslav Michael
    CIRCULATION JOURNAL, 2019, 83 (03) : 595 - +